Dacarbazine combined targeted therapy versus dacarbazine alone in patients with malignant melanoma: a meta-analysis

Area of Science:

• Oncology
• Dermatology

Background:

• Malignant melanoma is an aggressive skin cancer with limited treatment options.
• Dacarbazine (DTIC) is a standard first-line treatment for metastatic melanoma, but its efficacy is often limited.
• Low response rates with single-agent DTIC necessitate exploration of alternative therapeutic strategies.

Purpose of the Study:

• To compare the efficacy and safety of DTIC monotherapy versus DTIC-based combination therapies in advanced metastatic melanoma.
• To evaluate overall response and 1-year survival rates in patients receiving different DTIC treatment regimens.
• To assess the incidence of adverse events associated with DTIC-based combination treatments.

Main Methods:

• A meta-analysis of nine randomized controlled trials (RCTs) involving 2,481 patients was conducted.
• Literature search was performed across major electronic databases from 2003 to 2013.
• Primary outcomes included overall response and 1-year survival; secondary outcomes focused on adverse events.

Main Results:

• DTIC-based combination therapies demonstrated superior overall response rates (RR = 1.60, 95% CI: 1.27-2.01) compared to DTIC alone.
• A significant improvement in 1-year survival was observed with combination therapies (RR = 1.26, 95% CI: 1.14-1.39).
• Combination therapies were associated with increased adverse events, including nausea (RR = 1.23), vomiting (RR = 1.73), and neutropenia (RR = 1.75).

Conclusions:

• DTIC-based combination therapies offer a moderate improvement in overall response and 1-year survival for metastatic melanoma.
• The enhanced efficacy of combination therapies comes at the cost of an increased incidence of adverse events.
• Further large-scale, high-quality, placebo-controlled, double-blind trials are warranted to validate these findings.